Combination drug study for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This study tests two cancer drugs (benmelstobart and anlotinib) together to treat alveolar soft part sarcoma, a rare soft tissue cancer that has spread or cannot be surgically removed. The drugs work by boosting the immune system and blocking tumor blood vessel growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 14 years old
- You have been diagnosed with alveolar soft part sarcoma that is advanced, spread to other parts of the body, or cannot be surgically removed, and you have never received chemotherapy or other systemic cancer treatment for it
- Your overall health and ability to function in daily life is good (ECOG score 0–1, meaning you can do most normal activities)
- Your blood counts, liver function, and kidney function meet minimum safe levels for the study
- You have not had another cancer in the past 5 years (some exceptions apply, like cured skin cancer or cervical cancer in situ)
- You are willing to use effective birth control during the study and for 6 months after, and agree not to become pregnant or father children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
Hear when a new Alveolar Soft Part Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.